S 1090

structure given in first source

Also Known As:

(6R,7R)-7-((Z)-2-(2-amino-4-thiazolyl)-2-hydroxyiminoacetamido)-8-oxo-3-(1,2,3-triazol-5-yl)thiomethylthio-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; S-1090

Networked: 10 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Lactams: 2198
    - beta-Lactams: 2386
      - Cephalosporins: 4007
        S 1090: 10
- Sulfur Compounds: 278
  - Thiazines: 3
    - Cephalosporins: 4007
      - S 1090: 10
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - beta-Lactams: 2386
      - Cephalosporins: 4007
        S 1090: 10

Experts

1.	Ikeuchi, K: 3 articles (05/2001 - 05/2001)
2.	Kishi, K: 3 articles (05/2001 - 05/2001)
3.	Furukawa, H: 2 articles (05/2001 - 05/2001)
4.	Hara, K: 2 articles (05/2001 - 05/2001)
5.	Hirashiba, M: 2 articles (05/2001 - 05/2001)
6.	Hishikawa, A: 2 articles (05/2001 - 05/2001)
7.	Kanamori, S: 2 articles (05/2001 - 05/2001)
8.	Kaneto, M: 2 articles (05/2001 - 05/2001)
9.	Kato, I: 2 articles (05/2001 - 05/2001)
10.	Kawai, M: 2 articles (05/2001 - 05/2001)

Related Diseases

1.	Respiratory Tract Infections (Respiratory Tract Infection) 11/01/1995 - "The in vivo efficacy of S-1090 against systemic and urinary and respiratory tract infections caused by gram-positive and -negative bacteria was superior to that expected from the in vitro and in vivo activities of the agents against which it was compared."
2.	Endometritis 05/01/1998 - "The in vivo efficacy of S-1090 was evaluated using uterine endometritis of model rats. "
3.	Fetal Weight 05/01/2001 - "No effects of S-1090 were noted in the number of corpora lutea, number of implantations, implantation rate, death or resorption rate, number of live fetuses, sex ratio of live fetuses, fetal body weight of either sex, incidence of external anomalies, incidence of skeletal anomalies or variations, degree of ossification, or incidence of visceral anomalies. " 05/01/2001 - "No effects of S-1090 were observed in the implantation ratio, embryo-fetal viability, fetal body weight, and incidence of external, skeletal and visceral anomalies. "
4.	Infections 06/01/1998 - "In-vitro activity of S-1090, a novel oral cephalosporin, against bacteria causing infections in obstetric and gynaecological patients." 05/01/1998 - "S-1090 is a promising oral cephalosporin antibiotic for the treatment of infections in the fields of obstetrics and gynecology."
5.	Body Weight (Weight, Body) 05/01/2001 - "Body weight gain was increased from the early stage of administration to the end of pregnancy, food consumption was transiently decreased at the early stage of administration, and water consumption was increased from the middle to the end of pregnancy in all the S-1090 dosing groups. " 05/01/2001 - "In females, body weight gain was restrained during late pregnancy, and food consumption was decreased transiently following the initiation of dosing, and then remained high on the day before parturition in all the S-1090 dosing groups. "

Related Drugs and Biologics

1.	Cephalosporins (Cephalosporin Antibiotics)
2.	Antigens